Literature DB >> 30796456

The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial.

Johan S Bundgaard1, Jens J Thune1,2, Jens C Nielsen3, Regitze Videbæk1, Jens Haarbo4, Niels E Bruun5,6,7, Lars Videbæk8, David Aagaard1, Eva Korup9,10, Gunnar Jensen5, Per Hildebrandt5,11, Flemming H Steffensen12, Hans Eiskjær3, Axel Brandes8, Anna M Thøgersen9,10, Thomas M Melchior5, Ole D Pedersen5, Finn Gustafsson1, Kenneth Egstrup8, Christian Hassager1, Jesper H Svendsen1, Dan E Høfsten1, Christian Torp-Pedersen9,10, Susanne S Pedersen8,13, Steen Pehrson1, Lars Køber1, Ulrik M Mogensen1,5.   

Abstract

AIM: The Danish Study to Assess the Efficacy of Implantable Cardioverter-Defibrillators (ICD) in Patients with Non-ischaemic Systolic Heart Failure (HF) on Mortality (DANISH) found no overall effect on all-cause mortality. The effect of ICD implantation on health-related quality of life (HRQoL) remains to be established as previous trials have demonstrated conflicting results. We investigated the impact of ICD implantation on HRQoL in patients with non-ischaemic systolic HF, a prespecified secondary endpoint in DANISH. METHODS AND
RESULTS: In DANISH, a total of 1116 patients with non-ischaemic systolic HF were randomly assigned (1:1) to ICD implantation or usual clinical care (control). Patients completed disease-specific HRQoL as assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ; 0-105, high indicating worse). Changes in HRQoL 8 months after randomization were assessed with a mixed-effects model. At randomization, MLHFQ was completed by 935 (84%) patients (n = 472 in the ICD group and n = 463 in the control group) and was reassessed in 274 (58%) and 292 (63%) patients, respectively after 8 months for the primary analysis. Patients in the ICD group vs. the control group had similar improvements in MLHFQ after 8 months [least square mean -7.0 vs. -4.2 (P = 0.13)]. A clinically relevant improvement (decrease ≥5) in the MLHFQ overall score at 8 months was observed in 151 patients in the ICD group and 148 patients in the control group [55% vs. 51%, respectively (P = 0.25)].
CONCLUSION: Implantable cardioverter-defibrillator implantation in patients with non-ischaemic systolic HF did not significantly alter HRQoL compared with patients randomized to usual clinical care. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular disease; Heart failure; Implantable cardioverter-defibrillator; Quality of life

Year:  2019        PMID: 30796456     DOI: 10.1093/europace/euz018

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial.

Authors:  Johan S Bundgaard; Kasper Iversen; Mia Pries-Heje; Nikolaj Ihlemann; Sabine U Gill; Trine Madsen; Hanne Elming; Jonas A Povlsen; Niels E Bruun; Dan E Høfsten; Kurt Fuursted; Jens J Christensen; Martin Schultz; Flemming Rosenvinge; Jannik Helweg-Larsen; Lars Køber; Christian Torp-Pedersen; Emil L Fosbøl; Niels Tønder; Claus Moser; Henning Bundgaard; Ulrik M Mogensen
Journal:  Qual Life Res       Date:  2022-03-29       Impact factor: 3.440

2.  Health status measured by Kansas City Cardiomyopathy Questionnaire-12 in primary prevention implantable cardioverter defibrillator patients with heart failure.

Authors:  Gustav Mattsson; Marita Wallhagen; Peter Magnusson
Journal:  BMC Cardiovasc Disord       Date:  2021-08-28       Impact factor: 2.298

Review 3.  The Impact of Cardiac Devices on Patients' Quality of Life-A Systematic Review and Meta-Analysis.

Authors:  Kevin Willy; Christian Ellermann; Florian Reinke; Benjamin Rath; Julian Wolfes; Lars Eckardt; Florian Doldi; Felix K Wegner; Julia Köbe; Nexhmedin Morina
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10

4.  Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.

Authors:  Reece Holbrook; Lucas Higuera; Kael Wherry; Dave Phay; Yu-Cheng Hsieh; Kuo-Hung Lin; Yen-Bin Liu
Journal:  PLoS One       Date:  2020-11-19       Impact factor: 3.240

5.  Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial.

Authors:  Bruce L Wilkoff; Giuseppe Boriani; Suneet Mittal; Jeanne E Poole; Charles Kennergren; G Ralph Corey; Andrew D Krahn; Edward J Schloss; Jose L Gallastegui; Robert A Pickett; Rudolph F Evonich; Steven F Roark; Denise M Sorrentino; Darius P Sholevar; Edmond M Cronin; Brett J Berman; David W Riggio; Hafiza H Khan; Marc T Silver; Jack Collier; Zayd Eldadah; Reece Holbrook; Jeff D Lande; Daniel R Lexcen; Swathi Seshadri; Khaldoun G Tarakji
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-09-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.